Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren + ramipril + amlodipine vs dual combinations in essential hypertension with metabolic syndrome
2007-003677-10Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in essential hypertension and cardiometabolic risk (CMR) comparing Aliskiren + ramipril + amlodipine, Ramipril + amlodipine and Aliskiren + amlodipine (3 arms). Started Mar 2008; status: completed.
02
Drugs
aliskirenramiprilamlodipine
03
Conditions
essential hypertensioncardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2007-003677-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003677-10.